FreeTheAI

Disc Medicine Stock Surges 32% Premarket Ahead of Phase 3 Trial Results

BullishHigh impact
IRON$56.84 0.34%

Disc Medicine, Inc. (IRON) shares surged 32% in premarket trading on Monday ahead of late-stage clinical trial results for its experimental drug bitopertin. The company scheduled an 8 a.m. ET webcast on October 19 to discuss the outcome.

The Phase 3 APOLLO study evaluated 183 participants in a placebo-controlled trial testing bitopertin as a treatment for erythropoietic protoporphyria. The rare disorder causes severe and painful sensitivity to sunlight. Researchers measured changes in participants' sunlight tolerance alongside blood levels of metal-free protoporphyrin IX, a compound that builds up in patients and triggers severe light sensitivity.

The data marks a significant milestone following a February Complete Response Letter from the U.S. Food and Drug Administration, which requested additional evidence to support approval. Disc Medicine plans to use the APOLLO trial results to address those regulatory concerns, with an updated decision expected by mid-2027.

Key points

  • Disc Medicine (IRON) stock jumped 32% in premarket trading on Monday prior to releasing Phase 3 trial results.
  • The 183-participant APOLLO trial evaluated bitopertin for treating erythropoietic protoporphyria, a rare sunlight sensitivity disorder.
  • The study measured participant sunlight tolerance and blood levels of metal-free protoporphyrin IX.
  • Disc Medicine plans to leverage the data to satisfy FDA concerns, targeting an updated decision by mid-2027.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

Why did Disc Medicine shares surge on October 19?

Disc Medicine stock jumped 32% in premarket trading ahead of topline Phase 3 trial results for its rare disease drug bitopertin.

What condition is bitopertin designed to treat?

Bitopertin is an experimental treatment for erythropoietic protoporphyria, a rare disorder that causes severe and painful sensitivity to sunlight.

When is the next regulatory decision expected for bitopertin?

Disc Medicine plans to submit the APOLLO trial data to address FDA concerns, aiming for an updated regulatory decision by mid-2027.